Ann: Race Initiates Heart Safety Preclinical Study for Bisantrene, page-177

Also, we have had the perfect storm of bad news IMO:

1. Dr T leaving
2. Interest rates peaking
3. Tax loss selling
4. Radio silence on FA
5. Strategy update / DCB resigning

Not sure there could be much more negative news. Think we would have to be scrapping the bottom of the barrel apart from a cap raise but don't see that happening right for the foreseeable future, bigger fish to fry.

On the bright side, before Sheba 2 has officially wrapped up recruitment they are so confident that Prof Nagler already booking into ASH2023. That has to tell you something, especially the last two recruits wont impact on the findings.

Formulation RC220 must be getting close. This has to be a critical, whilst there is risk for any reformulation, I rely on the experts and they are not really concerned. The API Bisantrene is the same so more a delivery mechanism for reformulation so fingers crossed.

There is likely a stockpile of progress we just haven't heard about yet?

- FTO 100+ Program
- Cardio Protect MOA
- Dominissini Data
- Companion Diagnostics / Genomics
- RC330 Injectable
- NMR Program (ALKBH5/FTO)
- MRRF Grant Program outcomes
- Lung Cancer PD1 - Other
- Further appointments

CSO and fulltime CEO roles still to be filled. Pete Smith may be interim Exec Director, but may have contacts of a fulltime CEO. I am guessing that both CEO/CSO roles will be filled by the AGM - Watch this space!